Merus (NASDAQ:MRUS) Expected to Post FY2024 Earnings of ($3.66) Per Share

Merus (NASDAQ:MRUS) – Equities researchers at Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for Merus in a report released on Wednesday, April 24th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings of ($3.66) per share for the year, down from their prior forecast of ($3.54). The consensus estimate for Merus’ current full-year earnings is ($3.31) per share. Leerink Partnrs also issued estimates for Merus’ Q4 2024 earnings at ($1.09) EPS, FY2025 earnings at ($4.16) EPS and FY2026 earnings at ($0.84) EPS.

Several other equities research analysts have also recently issued reports on the company. William Blair reiterated an “outperform” rating on shares of Merus in a research note on Monday, April 22nd. BMO Capital Markets boosted their price objective on shares of Merus from $49.00 to $58.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Needham & Company LLC restated a “buy” rating and set a $66.00 price objective on shares of Merus in a research report on Thursday, April 11th. HC Wainwright boosted their price objective on shares of Merus from $48.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Finally, Truist Financial began coverage on shares of Merus in a research report on Thursday, March 28th. They set a “buy” rating and a $69.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $56.33.

Merus Trading Up 0.2 %

Shares of MRUS stock opened at $45.04 on Monday. The stock has a market cap of $2.64 billion, a P/E ratio of -14.82 and a beta of 1.10. The stock has a 50 day simple moving average of $45.03 and a 200 day simple moving average of $34.00. Merus has a 1 year low of $18.21 and a 1 year high of $52.03.

Merus (NASDAQ:MRUS) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.38). The company had revenue of $8.94 million during the quarter, compared to the consensus estimate of $10.43 million. Merus had a negative net margin of 352.56% and a negative return on equity of 50.61%.

Institutional Trading of Merus

A number of institutional investors and hedge funds have recently bought and sold shares of MRUS. Quadrant Capital Group LLC boosted its position in Merus by 37.7% during the fourth quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 343 shares during the last quarter. BluePath Capital Management LLC bought a new position in Merus in the 3rd quarter valued at about $33,000. China Universal Asset Management Co. Ltd. lifted its position in Merus by 142.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 867 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Merus in the 1st quarter valued at about $72,000. Finally, Tower Research Capital LLC TRC lifted its position in Merus by 64.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 828 shares in the last quarter. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.